Vol. 12, No. 1, June 2025, ISSN: 2049-4963

www.ijbmsp.org

Nanotechnology in Cancer Therapy: Current Trends, Challenges, and Future Prospects

Umaima Khan[1], Nazar Muhammad[1], Sania Ikram[1], Haider Ali[2], Zubair Ahmad[2], Zoha Waheed Abbasi[1], Zoya Amin[3*]

[1]Department of Biological Sciences, National University of Medical Sciences (NUMS), Rawalpindi, Punjab, Pakistan

[2] Kohat University of Science and Technology, Kohat 26000, Khyber Pakhtunkhwa, Pakistan

[3]Department of Pharmaceutics, Salim Habib University, Karachi, 74900, Pakistan

Email: zoya.amin45@gmail.com

Abstract – Cancer remains one of the leading causes of morbidity and mortality worldwide, despite advancements in conventional therapies such as surgery, chemotherapy, and radiotherapy. These traditional approaches often suffer from limitations including systemic toxicity, multidrug resistance, and poor specificity. Nanotechnology has emerged as a promising frontier in oncology, offering innovative strategies to enhance drug delivery, improve targeting accuracy, and integrate diagnostics with therapeutics [1]. This review provides a comprehensive overview of current nanocarriers—ranging from lipid-based and polymeric nanoparticles to inorganic and carbon-based nanomaterials—and highlights their applications in various therapeutic modalities, including chemotherapy, photothermal and photodynamic therapy, gene delivery, and immunotherapy [2]. It further discusses targeting strategies such as passive, active, and stimuli-responsive delivery systems, which improve tumor localization and therapeutic outcomes. Despite significant preclinical success, nanomedicine still faces several translational challenges, including nanotoxicity, tumor heterogeneity, biodistribution variability, and regulatory complexities. Emerging innovations such as personalized nanomedicine, AI-guided design, organoid models, and theranostic platforms are poised to overcome these hurdles and reshape the future of cancer treatment. This review underscores the transformative potential of nanotechnology in oncology while addressing the critical barriers to its clinical translation and widespread adoption.

Keywords – Nanotechnology, photodynamic therapy, Drug Development, Drug Delivery Systems, Personalized Medicine, polymeric nanoparticles, Immunotherapy.

1. Introduction

Cancer remains one of the leading causes of morbidity and mortality worldwide, accounting for approximately 10 million deaths annually [3]. Despite decades of research and significant advances in medical technologies, the management of cancer remains a formidable challenge. Conventional therapeutic modalities such as chemotherapy, radiotherapy, and surgery have been the mainstay of cancer treatment. However, these approaches are often accompanied by severe systemic toxicity, non-specific targeting, multidrug resistance (MDR), and limited efficacy in advanced or metastatic stages. Chemotherapeutic agents, while potent, lack selectivity, resulting in damage to healthy tissues and serious side effects such as immunosuppression, organ toxicity, and secondary malignancies. Moreover, radiotherapy is limited by radiation resistance in some tumors and potential damage to surrounding organs [4]. Surgical interventions are not always feasible, particularly when tumors are inoperable or have metastasized [5]. These limitations underscore the urgent need for more precise, effective, and safer treatment options that can overcome the shortcomings of traditional methods [6]. As the global cancer burden continues to rise, there is a growing consensus in the scientific community that a paradigm shift is needed in how cancer is detected, targeted, and treated.

Nanotechnology, the manipulation and application of materials at the nanometer scale (typically 1–100 nm), has emerged as a transformative field across multiple scientific domains. In biomedicine [7], nanotechnology offers the ability to design and fabricate multifunctional materials that interact with biological systems at the molecular level. These engineered nanomaterials can be tailored to possess unique physicochemical properties such as high surface area-to-volume ratio, tunable surface chemistry, enhanced permeability, and superior drug-loading capacity as in Figure 1. This nanoscale interaction enables precise control over drug release kinetics, biodistribution, and cell-targeting capabilities. In recent years, biomedical nanotechnology has given rise to the field of nanomedicine, encompassing diagnostics, drug delivery, imaging, and regenerative medicine [8]. Among its most promising applications is oncology, where nanotechnology has shown potential to revolutionize cancer detection, monitoring, and treatment [9]. By enabling site-specific delivery and minimizing systemic exposure, nanomedicine holds the promise of enhancing therapeutic outcomes while reducing adverse effects. Thus, nanotechnology has transitioned from being a novel concept to a viable clinical tool in modern cancer management [10].



Figure 1. Targeted gold nanoparticle system functionalized with PEG, Raman Reporter and EGFR-specific antibodies for cancer cell detection and binding.

The integration of nanotechnology in cancer therapy addresses several critical limitations of conventional treatment [11]. Nanocarriers can be engineered to exploit the enhanced permeability and retention (EPR) effect a phenomenon where nanoparticles preferentially accumulate in tumor tissues due to leaky vasculature and poor lymphatic drainage [12]. This passive targeting is further enhanced by active targeting strategies, wherein ligands such as antibodies, peptides, or small molecules are conjugated to nanoparticles for receptor-mediated uptake by cancer cells [13] [14]. Moreover, nanoparticles can encapsulate both hydrophilic and hydrophobic drugs, protect them from premature degradation, and enable controlled or stimuli-responsive release at the tumor site [15]. Multifunctional nanoplatforms also allow the co-delivery of chemotherapeutic agents, gene therapies, and immunomodulators, enabling synergistic therapeutic effects [16]. Additionally, nanotechnology facilitates the combination of therapy with real-time imaging (termed theranostics), allowing for better treatment planning and monitoring. In this way, nanomedicine has opened new avenues for personalized, targeted, and minimally invasive cancer treatments with the potential for significantly improved patient outcomes [17].

Over the past two decades, research in cancer nanotechnology has evolved from proof-of-concept studies to clinically relevant innovations. Several nano formulations have received regulatory approval, including liposomal doxorubicin (Doxil®), albumin-bound paclitaxel (Abraxane®), and iron oxide nanoparticles for imaging applications. These approvals mark critical milestones in the translation of nanomedicine into routine oncology practice [18]. Concurrently, a growing number of novel nanoplatforms—such as dendrimers, polymeric micelles, and inorganic nanoparticles—are under investigation in preclinical and clinical settings [19]. Many of these are designed to overcome drug resistance, enhance tumor penetration, or deliver combination therapies. Additionally, interdisciplinary collaborations between materials scientists, chemists, biologists, and clinicians have accelerated the development of innovative nanotherapeutic strategies [20]. However, despite this progress, significant challenges persist in scaling up production, ensuring long-term safety, and navigating complex regulatory pathways [21]. As the field matures, a clearer understanding of tumor biology and nano–bio interactions is guiding the design of next-generation nanomedicines tailored for specific cancers and patient profiles [22].

Given the rapid advancement and growing clinical interest in cancer nanotechnology, this review aims to provide a comprehensive overview of current trends, challenges, and future prospects in the field. We begin by exploring the various types of nanocarriers and platforms employed in cancer therapy, highlighting their design, mechanisms of action, and clinical relevance. The discussion extends to targeting strategies, including passive and active targeting, and the integration of stimuli-responsive systems. We also examine how nanotechnology enhances existing therapeutic modalities such as chemotherapy, phototherapy, gene delivery, and immunotherapy. A dedicated section focuses on the clinical translation of nano formulations, including regulatory approvals and ongoing trials. Furthermore, we address the challenges that hinder widespread adoption, such as toxicity concerns, manufacturing complexity, and tumor heterogeneity. Finally, we outline future directions, including smart nanoplatforms, personalized nanomedicine, and the convergence of artificial intelligence with nanotechnology. Through this synthesis, the review aims to inform researchers, clinicians, and policymakers about the transformative role of nanotechnology in the future of cancer therapy.

2. Overview of Nanocarriers and Nanoplatforms in Oncology

2.1. Lipid-Based Nanoparticles

Lipid-based nanoparticles are among the most established and widely studied nanocarriers in oncology due to their biocompatibility, ease of surface modification, and ability to encapsulate a wide range of therapeutic agents [23]. Liposomes, which are spherical vesicles composed of phospholipid bilayers, have been extensively used to encapsulate both hydrophilic and hydrophobic drugs. Their structural similarity to biological membranes enhances cellular uptake and reduces systemic toxicity. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are newer classes that offer better stability and controlled drug release profiles [24].

2.2. Polymeric Nanoparticles

Polymeric nanoparticles are another versatile platform for cancer therapy, especially valued for their tunable physicochemical properties, biodegradability, and controlled release capabilities [25]. Commonly used polymers include poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and chitosan, each offering unique advantages in drug delivery applications. PLGA, for instance, is FDA-approved and known for its slow degradation rate, making it ideal for sustained drug release [26]. PEGylation, the attachment of PEG chains to the nanoparticle surface, improves solubility, circulation time, and reduce immunogenicity. Chitosan, a natural polysaccharide, enhances mucoadhesiveness and allows pH-sensitive delivery, which is particularly useful in targeting the acidic tumor microenvironment [27]. These polymeric carriers can be engineered into various architectures—such as nanospheres, nanocapsules, and core-shell systems—each enabling the encapsulation of single or multiple drugs.

Moreover, smart polymeric systems respond to external stimuli such as temperature, pH, or enzymes, enabling on-demand release at the tumor site. These capabilities have positioned polymeric nanoparticles as an essential tool in the development of targeted and personalized cancer treatments [28].

2.3. Inorganic Nanoparticles

Inorganic nanoparticles offer unique optical, magnetic, and electronic properties that make them suitable for both therapeutic and diagnostic applications in cancer [29]. Among the most studied are gold nanoparticles (AuNPs), mesoporous silica nanoparticles (MSNs), and quantum dots (QDs) [30]. Gold nanoparticles are particularly attractive due to their photothermal properties; they can absorb near-infrared light and convert it into heat, enabling the selective ablation of cancer cells in photothermal therapy (PTT) [31]. Their surface can also be functionalized with targeting ligands or drugs, enhancing specificity and multifunctionality [32]. Mesoporous silica nanoparticles, with their highly ordered pore structures, offer high surface area and pore volume for drug loading, as well as tunable release kinetics. Quantum dots are semiconductor-based nanoparticles that emit fluorescence, making them valuable for high-resolution imaging and real-time tracking of therapeutic agents [33]. While these materials provide promising platforms for photodynamic therapy (PDT) and theranostics, their clinical application is still under investigation due to concerns about long-term toxicity and biodegradability. Nonetheless, inorganic nanoparticles continue to play a key role in advancing multimodal cancer treatments [34].

2.4. Carbon-Based Nanomaterials

Carbon-based nanomaterials, including carbon nanotubes (CNTs), graphene oxide (GO), and carbon dots (CDs), have gained significant attention for their unique structural, electrical, and drug-carrying properties [35].

Carbon nanotubes, with their hollow cylindrical structures, can efficiently transport drugs, genes, or proteins across cellular membranes [36] . Their high aspect ratio and surface area make them excellent candidates for targeted drug delivery and thermal ablation therapies. Graphene oxide, composed of single-layered carbon atoms with oxygen-containing groups, offers good water dispersibility and ample surface functionalization sites, allowing for the conjugation of therapeutic agents and targeting moieties [37]. Carbon dots, a newer class of nanomaterials, are small, fluorescent carbon nanoparticles known for their excellent biocompatibility and low toxicity [38]. They can be used both for imaging and drug delivery applications. These carbon-based materials exhibit excellent drug loading capacity, responsiveness to environmental triggers, and can be modified for enhanced targeting.

However, their potential for clinical translation requires further study to fully understand their in vivo behavior, biodistribution, and clearance mechanisms [39].

2.5. Other Emerging Nanostructures

Beyond the conventional nanocarriers, several emerging and hybrid nanostructures are showing promise in cancer therapy [40]. Dendrimers, highly branched synthetic macromolecules, offer a well-defined architecture with multiple terminal functional groups that can simultaneously carry drugs, imaging agents, and targeting ligands [41]. Their multivalency and precise molecular size enable controlled drug loading and release. Polymeric micelles, formed through the self-assembly of amphiphilic block copolymers, are particularly effective for delivering poorly soluble chemotherapeutic agents such as paclitaxel and doxorubicin. They can accumulate in tumor tissues via the EPR effect and be functionalized for active targeting. Nanogels, which are hydrogel nanoparticles [42], combine the advantages of hydrophilicity, biocompatibility, and stimuli-responsiveness, making them suitable for encapsulating a variety of therapeutic payloads [43]. Hybrid systems, integrating organic and inorganic components, are also under development to achieve multifunctionality, such as combining imaging, targeting, and treatment in a single platform [44]. These next generation nanoplatforms represent a new frontier in cancer nanomedicine, offering improved efficacy and safety profiles [45]. However, like other systems, they must undergo rigorous preclinical and clinical validation before widespread adoption [46].

3. Targeting Strategies for Cancer Therapy

Effective cancer therapy requires not only potent therapeutic agents but also precise delivery mechanisms that minimize systemic toxicity and maximize tumor-specific accumulation [47]. Nanotechnology has enabled the development of sophisticated delivery systems that can be directed toward tumor tissues through various targeting

strategies [2]. These strategies are generally categorized into passive targeting, active targeting, and stimuli-responsive targeting, each leveraging distinct biological or physicochemical principles to improve therapeutic precision

Passive targeting is primarily based on the Enhanced Permeability and Retention (EPR) effect, a phenomenon that arises from the unique vascular characteristics of solid tumors [49]. Tumor blood vessels are often poorly aligned, fenestrated, and lack effective lymphatic drainage, which allows nanoparticles typically in the size range of 10–200 nm to extravasate and accumulate in tumor tissues more readily than in normal tissues [50]. This passive accumulation enhances the local concentration of the therapeutic payload while reducing systemic distribution. Nanocarriers such as liposomes, polymeric nanoparticles, and micelles have been engineered to exploit the EPR effect by optimizing size, surface charge, and hydrophilicity to prolong circulation time and enhance tumor localization [51]. PEGylation, for instance, reduces opsonization and clearance by the mononuclear phagocyte system, thereby increasing the likelihood of tumor accumulation [52].

Despite its advantages, the EPR effect varies significantly across tumor types and between patients, and its efficiency is often limited by high interstitial fluid pressure or poor vascularization within the tumor mass depicted in **Figure 2**[53]. Therefore, while passive targeting forms the basis of many clinically approved nanomedicines, it is often complemented by active targeting strategies for improved precision [54].

3.1. Passive Targeting



Figure 2. Active and Passive targeted Drug Delivery

3.2. Active Targeting

Active targeting enhances the specificity of nanocarriers by functionalizing their surfaces with ligands that recognize and bind to overexpressed receptors on the surface of cancer cells or tumor vasculature [55]. This ligand-receptor-mediated interaction facilitates cell-specific uptake through endocytosis, thereby increasing intracellular drug delivery [56]. Common targeting ligands include folic acid, which binds to folate receptors frequently upregulated in ovarian, breast, and lung cancers; transferrin, which targets transferrin receptors overexpressed in rapidly dividing cells; and monoclonal antibodies such as trastuzumab, which targets HER2 receptors in breast cancer [57]. Peptides, aptamers, and small molecules are also increasingly being used for targeting due to their high affinity and low immunogenicity. Surface engineering techniques, such as click chemistry and carbodiimide coupling, are employed to stably attach these ligands to nanoparticle surfaces without affecting their stability or biodistribution [58].

By combining receptor-specific recognition with efficient drug encapsulation, actively targeted nanocarriers

can deliver therapeutic agents precisely to tumor cells, minimizing off-target effects and enhancing therapeutic outcomes. This approach is especially useful in heterogeneous tumors or those that are poorly accessible by passive targeting alone [59].

3.3. Stimuli-Responsive Nanocarriers

Stimuli-responsive nanocarriers represent a more dynamic targeting approach that leverages the physiological differences between tumor and normal tissues to trigger drug release [60]. These "smart" systems are engineered to respond to specific internal or external stimuli, ensuring that the therapeutic payload is released only under tumor-specific conditions. pH-responsive nanocarriers, for example, take advantage of the acidic tumor microenvironment (pH ~6.5) or the even lower pH within endosomes and lysosomes (pH ~5.5) to destabilize the nanoparticle structure and release the drug [61]. Temperature-sensitive systems exploit the fact that tumors often exhibit localized hyperthermia, or they can be externally activated by mild heating. Enzyme-responsive nanocarriers release their cargo in response to overexpressed enzymes in tumors, such as matrix metalloproteinases (MMPs) or cathepsins [62]. Redox-sensitive nanocarriers are triggered by the elevated levels of glutathione (GSH) in cancer cells, enabling controlled intracellular release [63].

By integrating one or more of these stimuli into the design, nanocarriers can achieve precise spatial and temporal control of drug delivery, reduce premature leakage, and overcome barriers such as multidrug resistance [64]. The development of multi-stimuli-responsive systems, which react to combinations of pH, temperature, and enzymatic cues, further enhances the selectivity and adaptability of cancer nanomedicines [65].

4. Nanotechnology-Enhanced Therapeutic Modalities

The integration of nanotechnology into cancer treatment has revolutionized traditional therapeutic modalities by enhancing efficacy, reducing systemic toxicity, and enabling precise tumor targeting [66]. Nanocarriers not only improve the pharmacokinetics and bioavailability of drugs but also introduce innovative strategies such as light-activated therapy, gene editing, and immunomodulation [67]. These nano-enabled platforms can function as monotherapies or be integrated into combination regimens to overcome multidrug resistance and tumor heterogeneity [68]. This section explores how nanotechnology is reshaping major therapeutic approaches in oncology, including chemotherapy, phototherapies, gene delivery, immunotherapy, and combination strategies [69].

4.1. Chemotherapy

Nanotechnology has significantly improved the delivery and performance of chemotherapeutic agents, which traditionally suffer from poor solubility, short half-life, and nonspecific distribution leading to systemic toxicity [70]. Nanocarriers such as liposomes, micelles, dendrimers, and polymeric nanoparticles have been designed to encapsulate cytotoxic drugs like doxorubicin, paclitaxel, and cisplatin, improving their solubility, stability, and circulation time [71]. Encapsulation also protects the drug from premature degradation and allows for controlled or sustained release at the tumor site. FDA-approved nanomedicines such as Doxil® (liposomal doxorubicin) and Abraxane® (albumin-bound paclitaxel) exemplify how nanoformulations can enhance therapeutic indices. Targeted nanocarriers further refine this by directing drugs specifically to tumor tissues through ligand-mediated interactions or the EPR effect. Overall, nanotechnology reduces off-target effects, enhances therapeutic efficacy, and opens the door to personalized chemotherapeutic regimens [66].

4.2. Photothermal and Photodynamic Therapy

Photothermal therapy (PTT) and photodynamic therapy (PDT) represent non-invasive treatment modalities that benefit substantially from nanotechnology [72]. In PTT, nanoparticles such as gold nanorods, carbon nanotubes, or MXenes absorb near-infrared (NIR) light and convert it into localized heat, inducing tumor cell apoptosis. PDT involves light-activated photosensitizers that generate reactive oxygen species (ROS) upon illumination, leading to cellular damage and death [73]. Nanocarriers improve the delivery of these agents by enhancing solubility, protecting them from photobleaching, and enabling tumor-specific accumulation [74]. Furthermore, stimuli-responsive and activatable nanoparticles ensure that these therapies are confined to the tumor site, minimizing damage to healthy tissues [75]. Multifunctional platforms combining PTT/PDT with imaging capabilities also support theranostic applications, enabling real-time monitoring of treatment response. These nanotechnology-assisted light therapies are especially promising for surface-accessible or deeply localized tumors when combined with optical fiber delivery [76] .

4.3. Gene and Nucleic Acid Delivery

Gene therapy has emerged as a powerful strategy for treating cancer by silencing oncogenes or reactivating tumor suppressor genes [77]. However, nucleic acids such as siRNA, miRNA, and plasmids are inherently unstable and prone to degradation by nucleases in systemic circulation [78]. Nanocarriers play a critical role in protecting these molecules and facilitating their intracellular delivery. Lipid nanoparticles (LNPs), polymeric vectors, and inorganic platforms (e.g., gold or silica-based) have been engineered to transport gene payloads safely to tumor cells. Surface modifications with targeting ligands improve cellular uptake and endosomal escape, critical for gene silencing activity [79].

Additionally, nanotechnology supports the delivery of CRISPR/Cas systems for genome editing, offering new avenues for precise genetic manipulation in cancer cells [80]. These nano-enabled platforms bypass many of the limitations associated with viral vectors, such as immunogenicity and integration risks, thereby expanding the scope of gene-based cancer therapies [81].

4.4. Immunotherapy Integration

Nanotechnology has found a critical role in the emerging field of cancer immunotherapy, offering tools to enhance immune activation, antigen presentation, and tumor-specific immune responses [82]. Nanoparticles can act as delivery vehicles for tumor antigens, immune adjuvants, or checkpoint inhibitors, creating synthetic "nano-vaccines" that stimulate robust anti-tumor immunity. For example, polymeric or lipid-based nanoparticles can co-deliver antigens and adjuvants to dendritic cells, boosting T cell activation. Nanocarriers are also employed to modulate

the tumor microenvironment (TME), reprogramming immunosuppressive cells or delivering small molecules that inhibit PD-1/PD-L1 or CTLA-4 checkpoints [83] [84]. Additionally, targeted delivery of cytokines or immune-stimulatory molecules reduces systemic toxicity while enhancing local immune responses. By precisely directing immunotherapeutic agents and minimizing immune-related adverse events, nanotechnology offers a promising strategy to potentiate the efficacy of immune- based cancer treatments [85].

4.5. Combination Therapies

Combination therapies involving multiple therapeutic agents are widely adopted in oncology to overcome drug resistance and enhance efficacy through synergistic effects [86]. Nanocarriers enable co-delivery of chemotherapeutics, gene therapies, immunomodulators, or photosensitizers within a single platform, ensuring that all agents reach the tumor site simultaneously and at optimal ratios [87]. This spatial and temporal co-localization is difficult to achieve with conventional delivery methods. For example, polymeric micelles or lipid-based vesicles can encapsulate hydrophilic and hydrophobic drugs together, while layered or core-shell nanoparticles enable sequential release of different agents [88]. Multifunctional platforms combining chemotherapy with PTT, PDT, or immunotherapy have demonstrated enhanced tumor regression in preclinical models. Such systems also offer the potential for integrated diagnosis and treatment (theranostics), which aids in real-time monitoring of therapeutic response [89]. Ultimately, nanotechnology-enabled combination therapy holds great promise for tackling complex, heterogeneous tumors and improving long-term patient outcomes [90].

5. Challenges and Limitations

Despite the promising advantages of nanotechnology in oncology, several critical challenges and limitations hinder its broad clinical translation [91]. One of the foremost concerns is nanotoxicity and long-term biocompatibility. Nanoparticles, especially inorganic and synthetic variants, may induce oxidative stress, inflammation, or genotoxicity upon accumulation in healthy tissues [92]. The interaction of nanoparticles with the immune system can trigger unintended immune responses, potentially leading to hypersensitivity or rapid clearance from the bloodstream [93]. Furthermore, the long-term fate of nanomaterials within the human body, particularly their degradation products and their accumulation in organs like the liver and spleen, remains an area requiring deeper investigation [94]. Another major limitation is the uncertain biodistribution and clearance profiles of many nanocarriers [95]. Although engineered for tumor targeting, nanoparticles often suffer from nonspecific uptake by the mononuclear phagocyte system (MPS), especially in the liver and spleen, reducing their therapeutic index. The variability of the Enhanced Permeability and Retention (EPR) effect across tumor types and between patients leads to inconsistent outcomes in drug accumulation and efficacy [51]. Tumors with dense stroma or poor vasculature may restrict nanoparticle penetration, while others may not exhibit strong EPR effects at all, undermining passive targeting strategies [96]. The heterogeneity of tumor biology adds another layer of complexity. Tumors differ vastly in size, microenvironment, antigen expression, and vascular architecture, all of which influence the interaction and performance of nanocarriers [97]. This biological variability makes it difficult to design a “one-size-fits-all” nanoparticle formulation, necessitating highly personalized or adaptable delivery systems.

Moreover, manufacturing and scale-up of nanomedicines present substantial technical and regulatory challenges [98]. Reproducibility, batch-to-batch consistency, and long-term stability are critical for clinical translation but difficult to achieve for complex multifunctional nanoparticles. Regulatory agencies, such as the FDA and EMA, demand rigorous characterization, toxicity profiling, and quality control, which are not yet standardized for nanoscale materials [98]. The lack of harmonized regulatory frameworks and validated preclinical models further impedes the timely approval of nanomedicines [99]. Addressing these multifaceted challenges requires a combination of interdisciplinary collaboration, technological innovation, and the establishment of robust regulatory science. Only through a concerted effort can the full potential of nanotechnology in cancer therapy be realized.

6. Future Prospects and Innovations

The future of nanotechnology in cancer therapy lies in the convergence of personalized medicine, biomimetic systems, and smart diagnostic-integrated platforms. One emerging frontier is personalized nanomedicine, wherein nanoparticles are designed based on individual patient profiles, including genetic, proteomic, and metabolic data [100]. The integration of artificial intelligence (AI) and machine learning enables predictive modeling of nanocarrier behavior, drug release kinetics, and tumor responses, allowing for data-driven design and optimization of nanotherapeutics. Advanced 3D tumor models, such as organoids and tumor-on-a-chip platforms, offer more physiologically relevant environments for evaluating nanoparticle efficacy and toxicity [101].

These preclinical tools bridge the gap between in vitro and in vivo systems, providing a powerful means to validate nanomedicine performance under patient-specific conditions.

Innovations in smart nanorobotics and autonomous delivery systems are also transforming the landscape. Nanorobots capable of navigating biological environments, responding to stimuli, and delivering payloads with extreme precision are under active investigation. Similarly, exosome-mimetic nanocarriers, derived from natural vesicles, exhibit high biocompatibility, immune evasion, and intrinsic targeting capabilities. Biogenic nanoparticles, synthesized using green chemistry or biosystems, emerge as sustainable and safer alternatives to conventional synthetic carriers. Moreover, the field of theranostics, which combines therapy and diagnostics into a single platform is gaining traction. Nanoparticles functionalized with imaging agents (e.g., MRI, PET, or fluorescence tags) allow for real-time tracking of biodistribution and therapeutic efficacy, enhancing clinical decision-making and treatment monitoring. Overall, the future promises a shift toward integrated, patient-specific, and smart nanoplatforms that not only treat cancer more effectively but also predict, monitor, and adapt to disease dynamics in real time.

7.

8. Conclusion

Nanotechnology has ushered in a new era in cancer therapy, offering revolutionary solutions to many of the limitations associated with conventional treatment modalities. Through enhanced targeting, controlled drug release, and integration with novel therapeutic techniques such as phototherapy, gene delivery, and immunotherapy, nanocarriers have shown great potential to transform oncological care. Clinically approved nanoformulations already demonstrate improved efficacy and reduced side effects, validating the relevance of nanotechnology in modern cancer treatment. However, the journey from bench to bedside remains fraught with scientific, technical, and regulatory hurdles. Challenges such as nanotoxicity, inconsistent biodistribution, tumor heterogeneity, and complex manufacturing processes must be systematically addressed. Furthermore, standardization in regulatory pathways and long-term clinical studies are essential to establish the safety and efficacy of nanomedicines at scale.

Nonetheless, emerging innovations such as AI-driven nanoparticle design, personalized medicine, and organoid-based testing platforms are expected to accelerate the development and clinical translation of next-generation nanotherapeutics. The exploration of biomimetic and multifunctional nanostructures offers new hope for overcoming biological barriers and enhancing patient-specific treatment responses. In conclusion, while nanotechnology in cancer therapy is still evolving, its impact is undeniably transformative. A future that combines intelligent design, translational research, and clinical precision may finally fulfill the promise of safe, targeted, and effective cancer nanomedicine paving the way for longer survival, improved quality of life, and potentially curative outcomes.

Acknowledgement:

Authors would like to acknowledge Department of Biological Sciences, National University of Medical Sciences (NUMS), Rawalpindi, Pakistan.

Conflict of Interest

Authors have no conflict of interest to declare.

References

[1] Khan, S.U., et al., Nanotherapeutic approaches for transdermal drug delivery systems and their biomedical applications. 2024. 207: p. 112819.

[2] Amin, Z., et al., Fundamentals of Nanotechnology, in Revolutionizing Agriculture: A Comprehensive Exploration of Agri-Nanotechnology. 2024, Springer. p. 1-16.

[3] Dunn, G.P., L.J. Old, and R.D.J.I. Schreiber, The immunobiology of cancer immunosurveillance and immunoediting. 2004. 21(2): p. 137-148.

[4] Heidary, N., H. Naik, and S.J.J.o.t.A.A.o.D. Burgin, Chemotherapeutic agents and the skin: an update. 2008. 58(4): p. 545-570.

[5] Demange, M.K. and F.J.C. Fregni, Limits to clinical trials in surgical areas. 2011. 66: p. 159-161.

[6] Alifah, N., et al., Development of clindamycin-releasing polyvinyl alcohol hydrogel with self-healing property for the effective treatment of biofilm-infected wounds. 2024. 10(7): p. 482.

[7] Ullah, M., et al., Stent as a novel technology for coronary artery disease and their clinical manifestation. 2023. 48(1): p. 101415.

[8] Biswas, P., C.-Y.J.J.o.t.a. Wu, and w.m. association, Nanoparticles and the environment. 2005. 55(6): p. 708-746.

[9] Waleed, A., et al., Nanotechnology and biomedical devices used as a novel tool in biosensing and bioimaging of disease. 2023. 1(4).

[10] Wang, M. and M.J.P.r. Thanou, Targeting nanoparticles to cancer. 2010. 62(2): p. 90-99.

[11] Ullah, M., et al., Cancer nanomedicine: Smart arsenal in the war against cancer. 2025: p. 114030.

[12] Park, J., et al., Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. 2019. 9(26): p. 8073.

[13] Das, M., C. Mohanty, and S.K.J.E.o.o.d.d. Sahoo, Ligand-based targeted therapy for cancer tissue. 2009. 6(3): p. 285-304.

[14] Safdar, M., et al., Cancer stem cell analysis and targeting. 2025.

[15] Valo, H., et al., Electrospray encapsulation of hydrophilic and hydrophobic drugs in poly (L-lactic acid) nanoparticles. 2009. 5(15): p. 1791-1798.

[16] de Dios, A.S. and M.E.J.A.c.a. Díaz-García, Multifunctional nanoparticles: analytical prospects. 2010. 666(1-2): p. 1-22.

[17] Ullah, H.A.M., et al., Induction of Pharmacists in Accident and Emergency Departments and Hospitals in Pakistan: A Case Study. 2021. 9(2).

[18] Zhao, N., et al., Advances in delivery systems for doxorubicin. 2018. 9(5): p. 519.

[19] Dri, D.A., et al., Surfactants, nanomedicines and nanocarriers: a critical evaluation on clinical trials. 2021. 13(3): p. 381.

[20] Goodlev, E.R., et al., Managing cancer pain, monitoring for cancer recurrence, and mitigating risk of opioid use disorders: A team-based, interdisciplinary approach to cancer survivorship. 2019. 22(11): p. 1308-1317.

[21] Fanciullino, R., J. Ciccolini, and G.J.C.r.i.o.h. Milano, Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. 2013. 88(3): p. 504-513.

[22] Ullah, S.H.M., et al., Confidence and Accuracy in identification of adverse drug reaction (ADR) reported by inpatients. 2023. 10(1).

[23] García-Pinel, B., et al., Lipid-based nanoparticles: application and recent advances in cancer treatment. 2019. 9(4): p. 638.

[24] Samimi, S., et al., Lipid-based nanoparticles for drug delivery systems. 2019: p. 47-76.

[25] Crucho, C.I., M.T.J.M.S. Barros, and E. C, Polymeric nanoparticles: A study on the preparation variables and characterization methods. 2017. 80: p. 771-784.

[26] Aftab, M., et al., Recent Trends and Future Directions in 3D Printing of Biocompatible Polymers. 2025. 9(4): p. 129.

[27] Chan, J.M., et al., Polymeric nanoparticles for drug delivery. 2010: p. 163-175.

[28] Ullah, M., et al., Clindamycin-loaded polyhydroxyalkanoate nanoparticles for the treatment of methicillin-resistant Staphylococcus aureus-infected wounds. 2024. 16(10): p. 1315.

[29] Pandey, P. and M.J.J.C.R. Dahiya, A brief review on inorganic nanoparticles. 2016. 3(3): p. 18-26.

[30] Kim, T. and T.J.N. Hyeon, Applications of inorganic nanoparticles as therapeutic agents. 2013. 25(1): p. 012001.Barbato, L., et al., Cancer Stem Cells and Targeting Strategies. *Cells*, 2019. **8(8)**.

[31] Khan, S.U., et al., Nanotherapeutic approaches for transdermal drug delivery systems and their biomedical applications. 2024. 207: p. 112819.

[32] Amin, Z., et al., Fundamentals of Nanotechnology, in Revolutionizing Agriculture: A Comprehensive Exploration of Agri-Nanotechnology. 2024, Springer. p. 1-16.

[33] Dunn, G.P., L.J. Old, and R.D.J.I. Schreiber, The immunobiology of cancer immunosurveillance and immunoediting. 2004. 21(2): p. 137-148.

[34] Heidary, N., H. Naik, and S.J.J.o.t.A.A.o.D. Burgin, Chemotherapeutic agents and the skin: an update. 2008. 58(4): p. 545-570.

[35] Demange, M.K. and F.J.C. Fregni, Limits to clinical trials in surgical areas. 2011. 66: p. 159-161.

[36] Alifah, N., et al., Development of clindamycin-releasing polyvinyl alcohol hydrogel with self-healing property for the effective

treatment of biofilm-infected wounds. 2024. 10(7): p. 482.

[37] Ullah, M., et al., Stent as a novel technology for coronary artery disease and their clinical manifestation. 2023. 48(1): p. 101415.

[38] Biswas, P., C.-Y.J.J.o.t.a. Wu, and w.m. association, Nanoparticles and the environment. 2005. 55(6): p. 708-746.

[39] Waleed, A., et al., Nanotechnology and biomedical devices used as a novel tool in biosensing and bioimaging of disease. 2023. 1(4).

[40] Wang, M. and M.J.P.r. Thanou, Targeting nanoparticles to cancer. 2010. 62(2): p. 90-99.

[41] Ullah, M., et al., Cancer nanomedicine: Smart arsenal in the war against cancer. 2025: p. 114030.

[42] Park, J., et al., Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. 2019. 9(26): p. 8073.

[43] Das, M., C. Mohanty, and S.K.J.E.o.o.d.d. Sahoo, Ligand-based targeted therapy for cancer tissue. 2009. 6(3): p. 285-304.

[44] Safdar, M., et al., Cancer stem cell analysis and targeting. 2025.

[45] Valo, H., et al., Electrospray encapsulation of hydrophilic and hydrophobic drugs in poly (L-lactic acid) nanoparticles. 2009. 5(15): p. 1791-1798.

[46] de Dios, A.S. and M.E.J.A.c.a. Díaz-García, Multifunctional nanoparticles: analytical prospects. 2010. 666(1-2): p. 1-22.

[47] Ullah, H.A.M., et al., Induction of Pharmacists in Accident and Emergency Departments and Hospitals in Pakistan: A Case Study. 2021. 9(2).

[48] Zhao, N., et al., Advances in delivery systems for doxorubicin. 2018. 9(5): p. 519.

[49] Dri, D.A., et al., Surfactants, nanomedicines and nanocarriers: a critical evaluation on clinical trials. 2021. 13(3): p. 381.

[50] Goodlev, E.R., et al., Managing cancer pain, monitoring for cancer recurrence, and mitigating risk of opioid use disorders: A team-based, interdisciplinary approach to cancer survivorship. 2019. 22(11): p. 1308-1317.

[51] Fanciullino, R., J. Ciccolini, and G.J.C.r.i.o.h. Milano, Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. 2013. 88(3): p. 504-513.

[52] Ullah, S.H.M., et al., Confidence and Accuracy in identification of adverse drug reaction (ADR) reported by inpatients. 2023. 10(1).

[53] García-Pinel, B., et al., Lipid-based nanoparticles: application and recent advances in cancer treatment. 2019. 9(4): p. 638.

[54] Samimi, S., et al., Lipid-based nanoparticles for drug delivery systems. 2019: p. 47-76.

[55] Crucho, C.I., M.T.J.M.S. Barros, and E. C, Polymeric nanoparticles: A study on the preparation variables and characterization methods. 2017. 80: p. 771-784.

[56] Aftab, M., et al., Recent Trends and Future Directions in 3D Printing of Biocompatible Polymers. 2025. 9(4): p. 129.

[57] Chan, J.M., et al., Polymeric nanoparticles for drug delivery. 2010: p. 163-175.

[58] Ullah, M., et al., Clindamycin-loaded polyhydroxyalkanoate nanoparticles for the treatment of methicillin-resistant Staphylococcus aureus-infected wounds. 2024. 16(10): p. 1315.

[59] Pandey, P. and M.J.J.C.R. Dahiya, A brief review on inorganic nanoparticles. 2016. 3(3): p. 18-26.

[60] Kim, T. and T.J.N. Hyeon, Applications of inorganic nanoparticles as therapeutic agents. 2013. 25(1): p. 012001.

[61] Ullah, M., et al., Modified gold and polymeric gold nanostructures: Toxicology and biomedical applications. 2021. 42: p. 100412.

[62] Kango, S., et al., Surface modification of inorganic nanoparticles for development of organic–inorganic nanocomposites—A review. 2013. 38(8): p. 1232-1261.

[63] Huang, H., et al., Inorganic nanoparticles in clinical trials and translations. 2020. 35: p. 100972.

[64] Zeb, F., et al., Nutrition and Dietary Intervention in Cancer: Gaps, Challenges, and Future Perspectives. 2024: p. 281-307.

[65] Kulsoom, J., et al., Nano-Based Drug Delivery Systems in Plants, in Revolutionizing Agriculture: A Comprehensive Exploration of Agri-Nanotechnology. 2024, Springer. p. 307-323.

[66] Dizaj, S.M., et al., Antimicrobial activity of carbon-based nanoparticles. 2015. 5(1): p. 19.

[67] Fritea, L., et al., Metal nanoparticles and carbon-based nanomaterials for improved performances of electrochemical (Bio) sensors with biomedical applications. 2021. 14(21): p. 6319.

[68] Díez-Pascual, A.M.J.I.J.o.M.S., Carbon-based nanomaterials. 2021, MDPI. p. 7726.

[69] Ullah, M., et al., Carbon Dots: New Rising Stars in the Carbon Family for Diagnosis and Biomedical Applications. 2024. 6(1): p. 1.

[70] Reddy, A.L.M., et al., Hybrid nanostructures for energy storage applications. 2012. 24(37): p. 5045-5064.

[71] Thorat, N.D. and J.J.A.S.S. Bauer, Functional smart hybrid nanostructures based nanotheranostic approach for advanced cancer treatment. 2020. 527: p. 146809.

[72] Hasan, N., et al., Nitric oxide-releasing self-healing hydrogel for antibacterial and antibiofilm efficacy against polymicrobial infection. 2024. 19(18): p. 1559-1571.

[73] Nawaz, K., et al., Tissue Engineering for Wound Healing: Recent Advancements and Opportunities, in Nanotechnology in Wound Healing. 2025, CRC Press. p. 149-167.

[74] Ali, A.A., et al., Gold-nanoparticle hybrid nanostructures for multimodal cancer therapy. 2022. 12(20): p. 3706.

[75] Safdar, M., et al., The evolving landscape of Biosafety and biosecurity: A review of international guidelines and best practices. 2023. 2(2).

[76] Hasan, N., et al., Recent advancements of nitric oxide-releasing hydrogels for wound dressing applications. 2023. 53(6): p. 781-801.

[77] Huang, P.S., A.J.C.o.i.g. Oliff, and development, Drug-targeting strategies in cancer therapy. 2001. 11(1): p. 104-110.

[78] Padma, V.V.J.B., An overview of targeted cancer therapy. 2015. 5: p. 1-6.

[79] Huynh, N.T., et al., The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. 2010. 5(9): p. 1415-1433.

[80] Alavi, M., M.J.D.m. Hamidi, and p. therapy, Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. 2019. 34(1): p. 20180032.

[81] Wu, J.J.J.o.p.m., The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. 2021. 11(8): p. 771.

[82] Suh, J., et al., PEGylation of nanoparticles improves their cytoplasmic transport. 2007. 2(4): p. 735-741.

[83] Maeda, H., et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. 2000. 65(1-2): p. 271-283.

[84] L Arias, J.J.M.r.i.m.c., Drug targeting strategies in cancer treatment: an overview. 2011. 11(1): p. 1-17.

[85] Bazak, R., et al., Cancer active targeting by nanoparticles: a comprehensive review of literature. 2015. 141: p. 769-784.

[86] Basile, L., R. Pignatello, and C.J.C.d.d. Passirani, Active targeting strategies for anticancer drug nanocarriers. 2012. 9(3): p. 255-268.

[87] Morales-Cruz, M., et al., Smart targeting to improve cancer therapeutics. 2019: p. 3753-3772.

[88] Kievit, F.M. and M.J.A.o.c.r. Zhang, Surface engineering of iron oxide nanoparticles for targeted cancer therapy. 2011. 44(10): p. 853-862.

[89] Bae, Y.H.J.J.o.c.r.o.j.o.t.C.R.S., Drug targeting and tumor heterogeneity. 2008. 133(1): p. 2.

[90] Zhang, Q., et al., Stimuli-responsive gene delivery nanocarriers for cancer therapy. 2023. 15(1): p. 44.

[91] Tian, M., et al., Advances in intelligent-responsive nanocarriers for cancer therapy. 2022. 178: p. 106184.

[92] Kuang, T., et al., Enzyme-responsive nanoparticles for anticancer drug delivery. 2016. 12(1): p. 38-46.

[93] Raza, A., et al., Redox-responsive nano-carriers as tumor-targeted drug delivery systems. 2018. 157: p. 705-715.

[94] Liu, J., et al., Design of nanocarriers based on complex biological barriers in vivo for tumor therapy. 2017. 15: p. 56-90.

[95] An, X., et al., Rational design of multi-stimuli-responsive

nanoparticles for precise cancer therapy. 2016. 10(6): p. 5947-5958.

[96] Emerich, D.F. and C.G.J.E.o.o.b.t. Thanos, Nanotechnology and medicine. 2003. 3(4): p. 655-663.

[97] Ullah, M., et al., Clinical applications of RNA editing technology for the early detection of cancer and future directions. 2020. 19: p. 1533033820964194.

[98] Ullah, M., et al., Smart Technologies used as Smart Tools in the Management of Cardiovascular Disease and their Future Perspective. Curr Probl Cardiol, 2023. 48(11): p. 101922.

[99] Nie, S., et al., Nanotechnology applications in cancer. 2007. 9(1): p. 257-288.

[100] Zhao, C.-Y., et al., Nanotechnology for cancer therapy based on chemotherapy. 2018. 23(4): p. 826.

[101] Estanqueiro, M., et al., Nanotechnological carriers for cancer chemotherapy: the state of the art. 2015. 126: p. 631-648.

[102] Shibu, E.S., et al., Nanomaterials formulations for photothermal and photodynamic therapy of cancer. 2013. 15: p. 53-72.

[103] Oh, J., H. Yoon, and J.-H.J.B.E.L. Park, Nanoparticle platforms for combined photothermal and photodynamic therapy. 2013. 3: p. 67-73.

[104] Tian, B., et al., Photothermally enhanced photodynamic therapy delivered by nano-graphene oxide. 2011. 5(9): p. 7000-7009.

[105] ur Rehman, K., et al., The Antibacterial Assessment of Biofabricated Magnesium Oxide Nanoparticles (MgO NPs) using Conocarpus erectus Leaf Extract. 2022. 1(2).

[106] Li, X., et al., Clinical development and potential of photothermal and photodynamic therapies for cancer. 2020. 17(11): p. 657-674.

[107] Mollé, L.M., et al., Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery. 2022. 14(6): p. e1809.

[108] Khan, S.U., et al., Single-cell RNA sequencing (scRNA-seq): advances and challenges for cardiovascular diseases (CVDs). 2024. 49(2): p. 102202.

[109] Chen, C., Z. Yang, and X.J.M.r.r. Tang, Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy. 2018. 38(3): p. 829-869.

[110] Ullah, I.J.G., CRISPR/Cas9-Based Genome Editing in Precision Medicine: Current Trends and Recent Advancements. 2024. 1: p. 100001.

[111] Ullah, A., et al., A review of recent advances in nanotechnology for the delivery of therapeutics in wound healing. 2025. 55(1): p. 33-54.

[112] Pitroda, S.P., S.J. Chmura, and R.R.J.T.L.O. Weichselbaum, Integration of radiotherapy and immunotherapy for treatment of oligometastases. 2019. 20(8): p. e434-e442.

[113] Ullah, M., et al., Coronavirus and its terrifying inning around the globe: The pharmaceutical cares at the main frontline. 2021. 275: p. 129968.

[114] Safdar, M., et al., Microbiome Miracles and their Pioneering Advances and Future Frontiers in Cardiovascular Disease. 2024: p. 102686.

[115] Araujo-Filho, I., A.C.M.J.J.O.S. do Rêgo, and C. RESEARCH, Nanotechnology and Immunetherapy: reduction of hepatotoxicity and anti-antineoplastic efficiency. 2024. 15(1): p. 59-78.

[116] Mokhtari, R.B., et al., Combination therapy in combating cancer. 2017. 8(23): p. 38022.

[117] Fischbach, M.A.J.C.o.i.m., Combination therapies for combating antimicrobial resistance. 2011. 14(5): p. 519-523.

[118] Zhou, Z., B.H. Edil, and M.J.B.m. Li, Combination therapies for cancer: challenges and opportunities. 2023. 21(1): p. 171.

[119] Abbas, A., et al., A comprehensive review: epidemiological strategies, catheterization and biomarkers used as a bioweapon in diagnosis and management of cardiovascular diseases. 2023. 48(7): p. 101661.

[120] Hu, C.-M.J., S. Aryal, and L.J.T.d. Zhang, Nanoparticle-assisted combination therapies for effective cancer treatment. 2010. 1(2): p. 323-334.

[121] Zheng, C., M. Li, and J.J.B.I. Ding, Challenges and opportunities of nanomedicines in clinical translation. 2021. 2(2): p. 57.

[122] Safdar, M., et al., Genomic insights into heart health: Exploring the genetic basis of cardiovascular disease. 2024. 49(1): p. 102182.

[123] Chang, C.J.J.o.a., The immune effects of naturally occurring and synthetic nanoparticles. 2010. 34(3): p. J234-J246.

[124] Ullah, M.J.J.o.W.M. and D. College, A Case Study: Psychophysiological Impact of Polycystic Ovarian Syndrome and its Management in Pakistani Women. 2022. 1(1).

[125] Li, S.-D. and L.J.M.p. Huang, Pharmacokinetics and biodistribution of nanoparticles. 2008. 5(4): p. 496-504.

[126] Miao, L., L.J.N.-B.P.T.f.t.D. Huang, and T.o. Cancer, Exploring the tumor microenvironment with nanoparticles. 2015: p. 193-226.

[127] Narang, A.S. and S.J.A.d.d.r. Varia, Role of tumor vascular architecture in drug delivery. 2011. 63(8): p. 640-658.

[128] Paliwal, R., R.J. Babu, and S.J.A.P. Palakurthi, Nanomedicine scale-up technologies: feasibilities and challenges. 2014. 15(6): p. 1527-1534.

[129] Nawaz, K., et al., Role of Nutrition in the Management of Inflammatory Bowel Disease. 2025. 5(1): p. 1-76.

[130] Hasan, N., et al., Nanoparticle-based drug delivery system for Oral Cancer: Mechanism, challenges, and therapeutic potential. 2025: p. 102068.

[131] Ullah, M., et al., Shaping the future of cardiovascular disease by 3D printing applications in stent technology and its clinical outcomes. 2024. 49(1): p. 102039.